Our Technology
AI-Powered Platforms
We address the entire spectrum of drug development. We use cutting-edge computational biology technologies for novel drug candidate discovery. We also specialize in co-developing novel drug response biomarkers of the existing drug candidates, which allows improvement of the likelihood of successful clinical trial, biomarker-driven indication expansion, and enhanced understanding of the drug's mechanism of action.
AI-Powered Platforms
-
Discovery platform :
Our analysis of genomics and 3D structure prediction of Targets enables a wide array of application in the oncologic and rare incurable diseases field
-
Predictive multi-biomarker discovery platform :
Our AI-based approach identifies predictive “multi-gene” biomarker for efficacy and safety from patient data during early phase clinical trials. AI-driven prediction model enhances the clinical trial success and enables biomarker-guided indication expansion/drug repositioning
-
AI-driven compound screening :
AI-based lead discovery as well as 2⁰ and/or off-target analysis and resistant biomarker identification-
Precise & efficient hit identification against a target protein
-
Lead optimization with computational screening
-
Simulation of structural impact of mutations in the target protein
-
Focusing on Intellectual Property in the following areas:
Artificial Intelligence (AI) Platform Technology
AI-driven drug development
Multi-gene Biomarker
Drug use patent
International Patent
Venture Intellectual Property
Fields of Expertise:
Medicine
Science
Biology
Chemistry
Computer & Technology
Environmental
Life Sciences
Medical Device
Nanotechnology